Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

On Thursday, Omeros Corporation OMER announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab.Omeros is a first-in-class monoclonal antibody that inhibits the lectin pathway of complement in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).TA-TMA is a complication in adult and pediatric hematopoietic stem cell transplantation (HSCT).The analysis compared overall survival in the 28 TA-TMA patients in OM ...